Prospective, International, Multicenter Minimal Interventional Study to Detect Possible Markers for Prediction of Seroma Development and Risk Assessment of a Breast Seroma After Mastectomy with or Without Implant-based Breast Reconstruction
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 2,000
- 试验地点
- 2
- 主要终点
- Identification of a patient population at increased risk for developing seroma.
研究概览
简要总结
The study is designed as international, prospective, minimal interventional study in cooperation with EUBREAST e.V. (European Breast Cancer Research Association of Surgical Trialists). Furthermore, it is planned to initiate a registry for postoperative breast seromas.
详细描述
Postoperative seroma formations are one of the most common and serious complications after breast surgery, above all after mastectomy. Especially in patients who have opted for breast reconstruction using implants, seromas lead to infections and wound dehiscence which can result in implant and finally breast loss. To date, the cause of seroma development has not yet been clarified. First data of a pilot study of our research group identified an association with immunological-inflammatory processes as a possible cause for seroma development (Seroma after Simple Mastectomy in Breast Cancer-The Role of CD4+ T Helper Cells and the Evidence as a Possible Specific Immune Process; Pochert et al. 2022).
The main objective of the SerMa (Seroma of the Mammary gland) study presented here is to identify patient groups who have an increased risk of developing seromas based on immunological/inflammatory processes. Based on the findings clinical consequences should be developed in the future, such as more precise risk-adapted patient education and individualized advising regarding the selection of the reconstruction procedure, with the goal of minimizing complication rates. In addition, analyses of the tumor and the microenvironment will be performed to differentiate possible carcinoma-specific immunological processes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •study group and control group 1:
- •Written informed consent
- •Age ≥ 18 years
- •all stages of DCIS or primary breast cancer (T1-T4, N0 or N+, M0) including all histopathological subtypes (ER/PR positive, ER positive/PR negative, Her-2/neu positive and triple negative)
- •Surgical procedure planned including ablatio or subcutaneous mastectomy with implant or expander insertion
- •Inclusion criteria control group 2 and 3:
- •Written informed consent
- •Age ≥ 18 years
- •Surgical procedure planned with implant or expander insertion with or without subcutaneous mastectomy
排除标准
- •Age <18 years
- •Breast cancer patients planned for breast conserving therapy
- •Recurrent breast cancer disease
- •History of breast surgery
- •Diagnosis of LCIS only
- •Pregnancy at time of diagnosis
- •Patients with a known immunodeficiency
结局指标
主要结局
Identification of a patient population at increased risk for developing seroma.
时间窗: Follow-up for each participant: 6 month
* Examination of seroma fluid and blood samples to identify immunological markers. * Local microbiome analyses to investigate a possible bacterial colonization. * Tissue analyses to determine possible carcinoma-specific immunologic processes.
次要结局
- Comparison of findings in local and systemic measurements in patients with and without seroma.(Follow-up for each participant: 6 month)
- Comparison of the groups with or without cancer regarding development of seroma.(Follow-up for each participant: 6 month)
- Comparison of the clinicopathologic differences between the implant and simple mastectomy group within both cancer groups(Follow-up for each participant: 6 month)
研究者
Nina Ditsch
Prof. Dr. med.
University Hospital Augsburg
